CAR-T Cell Therapy
NPTXR+ Solid Tumors
Key Facts
About Ymmunobio
Ymmunobio AG is a private, preclinical-stage biotech focused on a novel, pan-tumor target, NPTXR, aiming to develop targeted therapies with high tumor specificity and low off-target toxicity. The company employs a staged development strategy, prioritizing radiopharmaceuticals and BiTCEs for rapid IND filings and early human proof-of-concept, while advancing a dual-payload ADC as its flagship asset with clinical proof-of-concept targeted for 2028. With foundational IP protection until 2044 and a leadership team experienced in drug development, Ymmunobio is positioning itself to address a broad solid tumor market, though it faces significant risks typical of early-stage biotechs, including clinical, financial, and competitive challenges.
View full company profileAbout dr-reddys-laboratories
Founded in 1984, Dr. Reddy's has evolved from an API manufacturer into a fully integrated global pharmaceutical enterprise with a mission to provide affordable and innovative medicines. Its strategy is built on a four-pillar business model—Generics, API & Services, Innovative Medicines, and Consumer Health—leveraging deep scientific capabilities in complex generics, biosimilars, and novel drug discovery. Recent milestones, including the launch of India's first generic semaglutide and key biosimilar approvals in major markets, underscore its growth trajectory and commitment to addressing unmet patient needs globally.
View full company profileTherapeutic Areas
Other NPTXR+ Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Bispecific T-Cell Engager (BiTCE) | Ymmunobio | Preclinical |
| Dual-payload Antibody-Drug Conjugate (ADC) | Ymmunobio | Preclinical |